

13422 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

August 21, 1975

Page 2.

Whatever other fragmentary data that has appeared since 1970 have only served to support the general conclusions. It is interesting to me that the total efforts of the Committee on Care of the Diabetic has been directed to the criticism and denigration of the UGDP study and that no sound scientific evidence has been brought forth since the introduction of the oral hypoglycemic agents in 1955 to show any long-term benefit whatsoever. It is a sad commentary that despite the expenditure of some 10-15 billion dollars by the diabetic public throughout the world over these twenty years, the drug companies and their adherents have failed to come up with any studies that adequately prove that any reduction in morbidity and mortality has resulted from the long-term use of their drugs. If the logical concept of scientific proven benefit over risk as defined by the laws established by Congress in 1962 is to have any meaning for the twenty million to 30 million diabetic patients in the world the strongest possible warnings clearly stated should be implemented as soon as possible. The UGDP studies were published in 1970 and yet by August 1975 no clear labeling warning has as yet been issued by the government agency responsible by law to protect the American public.

I would appreciate having a transcript of the hearings of August 20th, 1975 when they are available.

Very truly yours

Max Miller

Max Miller, M. D.
Professor